Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E13.31 EPS (ttm)7.37 Insider Own0.40% Shs Outstand1.49B Perf Week-3.23%
Market Cap146.15B Forward P/E9.50 EPS next Y10.33 Insider Trans-22.32% Shs Float1.48B Perf Month-5.49%
Income12.10B PEG0.94 EPS next Q2.26 Inst Own86.10% Short Float3.78% Perf Quarter0.85%
Sales24.89B P/S5.87 EPS this Y306.10% Inst Trans-2.91% Short Ratio4.22 Perf Half Y-8.72%
Book/sh10.25 P/B9.57 EPS next Y8.11% ROA39.40% Target Price119.08 Perf Year38.48%
Cash/sh6.80 P/C14.43 EPS next 5Y14.18% ROE82.80% 52W Range63.50 - 116.83 Perf YTD4.11%
Dividend- P/FCF11.92 EPS past 5Y39.10% ROI44.80% 52W High-16.01% Beta0.79
Dividend %- Quick Ratio2.80 Sales past 5Y28.80% Gross Margin84.80% 52W Low54.54% ATR2.09
Employees7000 Current Ratio3.10 Sales Q/Q134.40% Oper. Margin61.30% RSI (14)38.67 Volatility2.41% 2.01%
OptionableYes Debt/Eq0.80 EPS Q/Q373.90% Profit Margin48.60% Rel Volume1.02 Prev Close100.69
ShortableYes LT Debt/Eq0.77 EarningsApr 21 AMC Payout0.00% Avg Volume13.27M Price98.13
Recom2.00 SMA20-2.83% SMA50-3.94% SMA200-1.65% Volume13,528,562 Change-2.54%
Feb-04-15Reiterated RBC Capital Mkts Outperform $125 → $118
Dec-23-14Reiterated Deutsche Bank Buy $142 → $125
Dec-09-14Reiterated Argus Buy $110 → $130
Oct-29-14Reiterated RBC Capital Mkts Outperform $115 → $125
Oct-13-14Reiterated FBR Capital Outperform $125 → $130
Sep-25-14Reiterated Needham Buy $95 → $120
Aug-22-14Reiterated RBC Capital Mkts Outperform $102 → $115
Aug-15-14Initiated FBR Capital Outperform $125
Aug-11-14Reiterated Argus Buy $90 → $110
Jul-28-14Reiterated Maxim Group Buy $112 → $127
Jul-24-14Reiterated RBC Capital Mkts Outperform $96 → $102
Apr-28-14Reiterated Maxim Group Buy $101 → $112
Feb-21-14Reiterated Barclays Overweight $90 → $95
Feb-10-14Reiterated Argus Buy $84 → $90
Feb-05-14Reiterated RBC Capital Mkts Outperform $90 → $96
Feb-05-14Reiterated Needham Buy $85 → $95
Feb-05-14Reiterated Maxim Group Buy $98 → $101
Feb-04-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
Jan-28-14Reiterated Deutsche Bank Buy $95 → $132
Jan-06-14Reiterated UBS Buy $80 → $102
Mar-31-15 07:06PM  Ascend Capital Opens New Position in Gilead Sciences
03:27PM  What to Look for This Earnings Season - Earnings Trends
03:27PM  What to Look for This Earnings Season - Earnings Outlook
02:48PM  Midday Glance: Biotechnology companies
01:09PM  Gilead Sciences Hovering Above Major Support Level
11:06AM  Post-UNH Deal, Spotlight on Pharmacy Benefit Stocks - Analyst Blog
10:54AM  Biotech: Why It's Not a Bubble at Barrons.com
Mar-30-15 06:55PM  Cramer: The best places for you to put new money at CNBC
05:32PM  UnitedHealth bulks up for prescription drug cost battle
03:07PM  Why Gilead Stock Could Rise
10:25AM  Why Citigroup Removed Gilead Sciences From Its 'Most Preferred' List at Barrons.com
10:07AM  Analyzing Pfizers Business Segments
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex - Press Releases
09:09AM  UnitedHealth's $12.8 Billion Answer To Expensive Prescription Drugs at Forbes
08:02AM  UnitedHealth to buy pharmacy benefits manager Catamaran AP
Mar-27-15 08:40PM  3 Under-the-Radar Risks for Gilead Sciences at Investopedia
07:26PM  Biotech bubble popped, time to buy again? at Fortune
06:19PM  Hot Stocks Gilead, Alaska Air Work On New Bases at Investor's Business Daily
04:53PM  Gilead CEO scores $187 million in 2014 gains at USA TODAY
03:14PM  Biotech bubble may just be an optical illusion at MarketWatch
02:51PM  Investors Might Want To Stay Away From This Biotech ETF
02:50PM  Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog
02:05PM  Not another Bubble: Why the NASDAQ is a Different Index Now
12:31PM  Experts Talking Gilead, Not Bubbles At Detroit's Engage Conference
12:16PM  Portfolio winner's top picks at Engage
11:11AM  Gilead Sciences: Harvoni Going Strong, Sovaldi Not So Much at Barrons.com
Mar-26-15 02:53PM  GenFit NASH Data Drives Up Rival Intercept at Investor's Business Daily
02:47PM  Is The Biotech Stock Correction A Buying Opportunity Or A Wake Up Call? at Forbes
02:01PM  A Bold Call on Biotech ETFs
12:12PM  Biotech Stock Selloff: Is It Justified? at Investor's Business Daily
10:22AM  Gilead Sciences: Big in Japan? at Barrons.com
10:21AM  Biotech Crash -- How Long Will It Last? at Forbes
09:30AM  The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex, Gilead and Amgen - Press Releases
08:35AM  WHO urges Europeans to work together to counter high drug prices Reuters
08:22AM  One analyst is convinced the biotech stock plunge is 'misguided'
02:14AM  Japans Ministry of Health, Labour and Welfare Approves Gileads SovaldiĀ® (sofosbuvir) for the Treatment of Genotype 2 Chronic Hepatitis C at noodls
02:00AM  Japans Ministry of Health, Labour and Welfare Approves Gileads SovaldiĀ® (sofosbuvir) for the Treatment of Genotype 2 Chronic Hepatitis C Business Wire
12:06AM  Biotech Stocks Deliver a Dose of Pain at The Wall Street Journal
Mar-25-15 07:24PM  Biotech Stocks Deliver a Dose of Pain at The Wall Street Journal
07:01PM  Read This Before You Sell Gilead Sciences at Investopedia
12:47PM  Top 10 New Stocks to Trade Like Hedge Funds Renaissance Technologies at TheStreet
12:43PM  US consumer stocks rise after Kraft and Heinz deal at Financial Times
11:50AM  Biotech's Rally Fuels Bubble Fears at The Wall Street Journal
10:28AM  Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst Blog
10:21AM  Why These Could Be 2015's 10 Best Biotech Stocks at Investopedia
08:45AM  Why Deutsche Bank Says to Buy Gilead and Vertex Pullbacks at 24/7 Wall St.
02:53AM  Top U.S. CEOs reaped billions from stock gains in recent years, Reuters analysis shows Reuters
Mar-24-15 11:52PM  [$$] Biotechs Rally Fuels Bubble Fears at The Wall Street Journal
01:50PM  The true value of a life is not about the pharmaceutical costs at Financial Times
01:32PM  Why Teva Pharmaceuticals Could Gain 25% at Barrons.com
10:10AM  Company News for March 24, 2015 - Corporate Summary
09:00AM  TG Therapeutics Is A Best Idea at Forbes
08:56AM  High Alert for Signs of Biotech Collapse Makes for Nervous Investors at TheStreet
Mar-23-15 10:38PM  Could Gilead's Dividend Have Additional Upside? at Investopedia
05:18PM  Vertex Falls Below Buy Point On Cystic-Fibrosis Drug Data
05:01PM  Red flags for biotech
04:53PM  Gilead Sciences (GILD) Stock Declined Today on Hepatitis C Treatment Warning at TheStreet
04:33PM  Wall St. slips after rally as dollar swings Reuters
04:15PM  Stocks Slump at the Close as Dollar's Decline Fails to Ignite Rally at TheStreet
04:10PM  Why Apple isn't among Morgan Stanleys favorite big stocks at MarketWatch
04:10PM  Gilead: Buy the Pullback at Barrons.com
03:42PM  Previewing the Q1 Earnings Season - Video Blog
03:37PM  Signs of Froth in the Biotech Sector
03:17PM  [video]Stocks Mixed as Fed's Fischer Says a Rate Hike is Likely This Year at TheStreet
03:04PM  US STOCKS-Wall St little changed as energy retreats
02:58PM  11 Promising New Drugs Expected to Make Billions in Sales at TheStreet
02:31PM  Gilead shares dip after warning about hepatitis C drug interaction Reuters
02:05PM  Is Antitrust a Risk in the PharmacyclicsAbbVie Merger?
01:43PM  Pro: Not too optimistic, you can pick & choose
12:52PM  Call of the Day: Downgrading Biogen
12:50PM  Apple climbs after $1tn valuation call at Financial Times
12:29PM  US STOCKS-Wall St little changed as energy pares gains
12:19PM  Gilead's Hepatitis Drugs Tripped By Old Heart Drug at Forbes
12:13PM  ICYMI: Pharmaceutical Stocks Are Moving Big On Monday
11:38AM  3 Biotech ETFs in Focus as Biogen Soars - ETF News And Commentary
11:28AM  Vertex Tumbles As Cystic Fibrosis Data Disappoints at Investor's Business Daily
11:21AM  Gilead Shares Reacting To Death Of Patient
11:05AM  Biotech stocks on pace to snap 8-day win streak as warnings abound at MarketWatch
11:01AM  Why This Analyst Thinks Gilead's Technicals Are Setting Up For A Break
10:48AM  Stocks Gain as Falling Dollar Boosts Oil and Energy Sector at TheStreet
10:48AM  Gilead Sciences' Hepatitis-C Warning a 'Non-Event,' 'Buy on Weakness' at Barrons.com
10:37AM  After strong week, US stock gains slow in morning trading
10:34AM  Genworth, Tenet top S&P 500 gainers; Vertex down on drug trial at MarketWatch
09:44AM  Mon., March 23: Watch Tenet Healthcare Stock at MarketWatch
09:16AM  Stock Futures Aim Mildly Lower; Dollar Dips, Tenet Jumps On JV at Investor's Business Daily
09:15AM  US STOCKS-Wall St to dip at the open after weekly gains; volatility eyed
09:13AM  Monsanto weed-killer cancer risk; Gilead's drug warning; Tenet jumps on deals
09:08AM  Morning Movers: Gilead Drops on Heart Patient Warning; Biogen Falls on Downgrade at Barrons.com
09:04AM  Big Pharma But Not Such Big Money at Forbes
08:39AM  Premarkets: 5 things to know before the open at CNNMoney.com
08:33AM  Gilead Shares Tumble On Drug Warning; Baird Says Buy
08:28AM  Stock Futures Inch Higher After Late-Week Rally; Oil Slides at TheStreet
08:25AM  Gilead's stock falls after HCV drug safety warning, but analyst sees buying opportunity at MarketWatch
08:12AM  Wall Street eyes Fed hints; Monsanto controversy; Starbucks' reversal
Mar-21-15 02:36PM  Gilead Warns After Hepatitis Patient on Heart Drug Dies at Bloomberg
02:36PM  Gilead Warns After Hepatitis Patient on Heart Drug Dies
Mar-20-15 07:44PM  Lightning Round: Too much competition in this at CNBC
07:26PM  Cramer Remix: Cha-ching! Time to cash in at CNBC
06:39PM  6 trades on surging biotech sector at CNBC
05:00PM  Big biotech plays: 6 hot trades
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with Bristol-Myers Squibb Company', Janssen R&D Ireland, and Japan Tobacco Inc. to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Whitley Richard JamesDirectorMar 02Option Exercise26.995,000134,95020,641Mar 03 04:12 PM
Carter Paul RutherfordEVP Commercial OpsMar 02Option Exercise80.652,000161,30047,439Mar 04 07:49 PM
Alton Gregg HEVP, Corp & Med AffairsMar 02Option Exercise19.0910,000190,850159,422Mar 04 07:49 PM
MARTIN JOHN CChairman and CEOMar 02Option Exercise14.50150,0002,175,3754,405,876Mar 04 07:48 PM
Alton Gregg HEVP, Corp & Med AffairsMar 02Sale103.6312,0001,243,615147,422Mar 04 07:49 PM
MARTIN JOHN CChairman and CEOMar 02Sale103.51150,00015,526,2454,255,876Mar 04 07:48 PM
Carter Paul RutherfordEVP Commercial OpsMar 02Sale104.182,000208,36445,439Mar 04 07:49 PM
Whitley Richard JamesDirectorMar 02Sale103.435,000517,13615,641Mar 03 04:12 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Option Exercise16.4070,0001,147,650235,168Feb 19 06:42 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Sale103.0170,0007,210,740165,168Feb 19 06:42 PM
WOLD OLSEN PERDirectorFeb 06Buy99.9210,000999,15088,173Feb 10 04:30 PM
MARTIN JOHN CChairman and CEOFeb 02Option Exercise14.50150,0002,175,3754,272,987Feb 04 08:15 PM
Washington Robin LEVP, CFOFeb 02Option Exercise25.1433,192834,58683,024Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Option Exercise19.0910,000190,850123,694Feb 04 08:51 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Option Exercise80.652,000161,30036,308Feb 04 08:52 PM
Whitley Richard JamesDirectorFeb 02Option Exercise26.995,000134,95020,641Feb 04 04:04 PM
MARTIN JOHN CChairman and CEOFeb 02Sale105.43150,00015,815,2494,122,987Feb 04 08:15 PM
Washington Robin LEVP, CFOFeb 02Sale105.3833,1923,497,66249,832Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Sale105.7312,0001,268,719111,694Feb 04 08:51 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Sale106.152,000212,31034,308Feb 04 08:52 PM
Whitley Richard JamesDirectorFeb 02Sale105.675,000528,35815,641Feb 04 04:04 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Option Exercise16.4070,0001,147,650189,302Jan 20 12:46 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Sale98.4770,0006,893,083119,302Jan 20 12:46 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Option Exercise36.721,00036,72035,308Jan 12 03:55 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Sale100.881,000100,88134,308Jan 12 03:55 PM
MARTIN JOHN CChairman and CEOJan 05Sale96.651009,6654,122,987Jan 06 04:20 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise19.095,00095,425120,694Jan 06 04:20 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise14.50150,0002,175,3754,272,987Jan 06 04:20 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Option Exercise40.561,00040,56035,308Jan 06 04:21 PM
Whitley Richard JamesDirectorJan 02Option Exercise26.995,000134,95020,641Jan 06 02:12 PM
Whitley Richard JamesDirectorJan 02Sale95.225,000476,10015,641Jan 06 02:12 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Sale95.051,00095,05034,308Jan 06 04:21 PM
MARTIN JOHN CChairman and CEOJan 02Sale95.11149,90014,257,7224,123,087Jan 06 04:20 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Sale95.177,000666,192113,694Jan 06 04:20 PM
Cogan John FrancisDirectorDec 22Option Exercise14.3426,000372,77568,405Dec 24 12:58 PM
Cogan John FrancisDirectorDec 22Sale95.0326,0002,470,75542,405Dec 24 12:58 PM
MILLIGAN JOHN FPresident and COODec 08Option Exercise8.01146,8231,175,3181,120,871Dec 10 05:32 PM
MILLIGAN JOHN FPresident and COODec 08Sale106.26146,82315,601,122974,048Dec 10 05:32 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise8.01140,6331,125,7674,263,620Dec 03 07:13 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise40.562,00081,12036,308Dec 03 07:14 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.2931,000752,947149,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Option Exercise26.995,000134,95020,641Dec 03 03:46 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale100.022,000200,03134,308Dec 03 07:14 PM
MARTIN JOHN CChairman and CEODec 01Sale100.72140,63314,164,8294,122,987Dec 03 07:13 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale100.7933,0003,325,922116,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Sale100.195,000500,96915,641Dec 03 03:46 PM
Cogan John FrancisDirectorNov 21Option Exercise14.3425,000358,43867,405Nov 25 04:10 PM
Cogan John FrancisDirectorNov 21Sale101.2325,0002,530,77042,405Nov 25 04:10 PM
MILLIGAN JOHN FPresident and COONov 07Option Exercise8.01146,8951,175,8941,120,943Nov 12 12:48 PM
MILLIGAN JOHN FPresident and COONov 07Sale107.37146,89515,772,736974,048Nov 12 12:48 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000055,832Nov 07 01:20 PM
Carter Paul RutherfordEVP Commercial OpsNov 04Option Exercise0.004,800037,044Nov 05 05:37 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Option Exercise40.563,000121,68035,244Nov 05 05:37 PM
Whitley Richard JamesDirectorNov 03Option Exercise26.995,000134,95020,641Nov 05 12:23 PM
MARTIN JOHN CChairman and CEONov 03Option Exercise8.01140,6251,125,7034,570,012Nov 05 02:05 PM
Washington Robin LEVP, CFONov 03Option Exercise25.1433,192834,58683,024Nov 05 08:06 PM
Whitley Richard JamesDirectorNov 03Sale112.025,000560,09015,641Nov 05 12:23 PM
MARTIN JOHN CChairman and CEONov 03Sale110.40140,62515,525,1024,429,387Nov 05 02:05 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Sale112.463,000337,38032,244Nov 05 05:37 PM
Washington Robin LEVP, CFONov 03Sale110.2633,1923,659,83749,832Nov 05 08:06 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Option Exercise40.562,00081,12034,244Oct 28 01:35 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Sale110.002,000220,00732,244Oct 28 01:35 PM
Cogan John FrancisDirectorOct 21Option Exercise14.3415,000215,06357,405Oct 23 01:54 PM
Cogan John FrancisDirectorOct 21Sale104.0815,0001,561,14942,405Oct 23 01:54 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise8.01146,8951,175,8941,120,943Oct 09 02:10 PM
MILLIGAN JOHN FPresident and COOOct 07Sale104.60146,89515,365,818974,048Oct 09 02:10 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise23.7631,000736,405153,694Oct 03 02:53 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise8.01140,6251,125,7034,570,012Oct 03 02:57 PM
MARTIN JOHN CChairman and CEOOct 01Sale105.91140,62514,893,8454,429,387Oct 03 02:57 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale105.9833,0003,497,259120,694Oct 03 02:53 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Option Exercise40.562,00081,12034,244Sep 30 01:19 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Sale107.472,000214,94532,244Sep 30 01:19 PM
Cogan John FrancisDirectorSep 22Option Exercise14.345,00071,68847,405Sep 24 01:20 PM
Cogan John FrancisDirectorSep 22Sale106.605,000532,98742,405Sep 24 01:20 PM
MILLIGAN JOHN FPresident and COOSep 08Option Exercise8.01146,8951,175,8941,120,943Sep 10 04:06 PM
MILLIGAN JOHN FPresident and COOSep 08Sale105.99146,89515,569,664974,048Sep 10 04:06 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Option Exercise23.7631,000736,405155,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Option Exercise8.01140,6251,125,7034,570,012Sep 04 05:09 PM
Whitley Richard JamesDirectorSep 02Option Exercise26.995,000134,95020,641Sep 04 04:31 PM
Whitley Richard JamesDirectorSep 02Sale108.105,000540,50015,641Sep 04 04:31 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Sale108.5833,0003,583,230122,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Sale108.64140,62515,277,9144,429,387Sep 04 05:09 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Option Exercise19.0910,000190,85042,244Aug 28 02:35 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Sale106.1610,0001,061,61832,244Aug 28 02:35 PM
Cogan John FrancisDirectorAug 21Option Exercise14.345,00071,68847,405Aug 25 12:21 PM
Cogan John FrancisDirectorAug 21Sale101.095,000505,44042,405Aug 25 12:21 PM
Washington Robin LEVP, CFOAug 14Option Exercise40.5633,5561,361,03183,388Aug 18 01:10 PM
Washington Robin LEVP, CFOAug 14Sale95.5633,5563,206,61149,832Aug 18 01:10 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Option Exercise26.9916,728451,48948,713Aug 12 04:25 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Sale91.5816,7281,531,88131,985Aug 12 04:25 PM
Whitley Richard JamesDirectorAug 01Option Exercise26.995,000134,95020,641Aug 05 05:31 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise0.002,500033,205Aug 05 05:31 PM
Washington Robin LEVP, CFOAug 01Option Exercise22.3030,600682,49080,432Aug 05 01:35 PM
MARTIN JOHN CChairman and CEOAug 01Option Exercise8.01140,6251,125,7034,570,012Aug 04 06:16 PM
MARTIN JOHN CChairman and CEOAug 01Sale91.53140,62512,871,8134,429,387Aug 04 06:16 PM
Washington Robin LEVP, CFOAug 01Sale91.4830,6002,799,34849,832Aug 05 01:35 PM
Whitley Richard JamesDirectorAug 01Sale91.005,000455,00015,641Aug 05 05:31 PM
MOORE NICHOLAS GDirectorJul 28Option Exercise26.6245,0001,197,67545,000Jul 30 12:17 PM
MOORE NICHOLAS GDirectorJul 28Sale90.5645,0004,075,4030Jul 30 12:17 PM
Cogan John FrancisDirectorJul 21Option Exercise14.345,00071,68847,405Jul 23 01:31 PM